S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC)

$14.68
+0.65 (+4.63 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$13.81
Now: $14.68
$15.16
50-Day Range
$10.37
MA: $12.33
$14.44
52-Week Range
$9.88
Now: $14.68
$26.89
Volume1.22 million shs
Average Volume417,853 shs
Market Capitalization$647.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.73 million
Book Value$3.94 per share

Profitability

Net Income$-142,570,000.00
Net Margins-3,745.97%

Miscellaneous

Employees170
Market Cap$647.43 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. View Revance Therapeutics' Earnings History.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Revance Therapeutics.

What price target have analysts set for RVNC?

9 analysts have issued 12-month price objectives for Revance Therapeutics' shares. Their predictions range from $17.83 to $50.00. On average, they expect Revance Therapeutics' share price to reach $34.35 in the next twelve months. This suggests a possible upside of 134.0% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

What is the consensus analysts' recommendation for Revance Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/9/2019)
  • 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)
  • 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)

Has Revance Therapeutics been receiving favorable news coverage?

Media headlines about RVNC stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Revance Therapeutics earned a news impact score of 0.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Revance Therapeutics.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,310,000 shares, an increase of 6.2% from the August 30th total of 5,000,000 shares. Based on an average daily volume of 356,600 shares, the days-to-cover ratio is currently 14.9 days. Currently, 13.9% of the shares of the company are short sold. View Revance Therapeutics' Current Options Chain.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), ACADIA Pharmaceuticals (ACAD), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), TransEnterix (TRXC), Celgene (CELG), EXACT Sciences (EXAS) and Genomic Health (GHDX).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $14.68.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $647.43 million and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is http://www.revance.com/.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  305 (Thanks for Voting!)
Underperform Votes:  285 (Thanks for Voting!)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel